| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA703527 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 133 mg/kg (1,5,9qd treatment schedule) dosage | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 2. | ALA879439 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 300 mg/kg (1 qd treatment schedule) dosage | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 3. | ALA703530 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 80 mg/kg (1-5qd treatment schedule) dosage | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 4. | ALA704401 | F | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 300 mg/kg (treatment of 1qd schedule) dosage | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 5. | ALA703943 | F | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 40 mg/kg (treatment of 1-5qd schedule) dosage | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 6. | ALA702727 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 133 mg/kg (1,5,9qd treatment schedule) dosage; Range is 15-22 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 7. | ALA702730 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 300 mg/kg (1 qd treatment schedule) dosage; Range is 19-23 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 8. | ALA701735 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 80 mg/kg (1-5qd treatment schedule) dosage; Range is 11-24 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 9. | ALA702181 | F | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 300 mg/kg (treatment of 1qd schedule) dosage; Range is 14->45 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 10. | ALA702187 | F | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 40 mg/kg (treatment of 1-5qd schedule) dosage; 24->45 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 11. | ALA708645 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 133 mg/kg (1,5,9qd treatment schedule) dosage | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 12. | ALA708647 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 300 mg/kg (1 qd treatment schedule) dosage | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 13. | ALA709277 | F | Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 80 mg/kg (1-5qd treatment schedule) dosage | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA709284 | F | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 300 mg/kg (treatment of 1qd schedule) dosage | Mus musculus | 2 | organism-based format | Scientific Literature | ||
| 15. | ALA708742 | F | Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 40 mg/kg (treatment of 1-5qd schedule) dosage | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 16. | ALA705241 | F | Antitumor activity against ic implanted L1210 lymphoid leukemia in mice expressed as active dose range (1,5,9qd treatment schedule) required to produce increase in life span by >25% was determined; Range 67-133 | Mus musculus | 1 | cell-based format | Scientific Literature | ||
| 17. | ALA705243 | F | Antitumor activity against ic implanted L1210 lymphoid leukemia in mice expressed as active dose range (1-5qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 40-80 | Mus musculus | 1 | cell-based format | Scientific Literature | ||
| 18. | ALA705246 | F | Antitumor activity against ic implanted L1210 lymphoid leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 200-400 | Mus musculus | 1 | cell-based format | Scientific Literature | ||
| 19. | ALA705249 | F | Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1-5qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 10-80 | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 20. | ALA705255 | F | Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 50-400 | Mus musculus | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!